iRhythm Technologies Inc (iRhythm) is a digital health company with a focus on the advancement of cardiac care. The company develops products and provides services to patients suffering from arrhythmias. The company’s product portfolio consists of long-term cardiac rhythm monitors and the Zio XT and Zio AT wearable patch-based biosensors. Its Zio service offers a platform for evaluating patients with suspected arrhythmias.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

iRhythm focuses its R&D efforts on the ongoing development and expansion of patch-based monitoring devices and related services. The company's R&D activities are centered on continuous improvement and extensions to existing products and services, international expansion, advancing technology offerings, customer workflow optimization, data analytics, developing clinical evidence, and solidifying its footprint in digital healthcare. The R&D unit of iRhythm is responsible for software development, algorithm and product development, regulatory affairs, and clinical research. This unit focuses on sustaining achieved improvements and delivering future innovations. As of December, 2025, iRhythm owned or retained an exclusive license to 59 issued patents from the U.S. Patent Office, 16 issued patents from the Japanese Patent Office, seven issued patents from the Australian Patent Office, five issued patents from the Canadian Patent Office, seven issued patents from the European Patent Office, seven issued patents from the Korean Patent Office, four issued patents from the Chinese Patent Office, and one issued patent from the Indian Patent Office. The company also had 65 pending patent applications globally. iRhythm entered into a Technology License Agreement with BioIntelliSense, Inc. for the development and commercialization of potential next-generation products and services. In FY2025, the company spent US$84.6 million on its R&D activities, which as a percentage of revenue stood at 11.3% and grew 18.3% YoY.